Skip to main content
Equibles

VNOV · VitaNova Life Sciences Corp

Track VNOV — free

Use VNOV with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VNOV.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.05 -0.45 (-10.00%) At close · Oct 20
Rebalance outlook locked
Market Cap
$34.18M
Shares
8.34M
Volume · Oct 20 385 Avg daily vol (7 sessions) 339

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$4.05 Open$4.10 Day$4.05–4.10 Available close range$1.38–4.50 Avg vol 30d723 Short int33 · 0.0% float Short vol100% DataApr 2022–Oct 2026 Filing10-Q · Sep 14

The closing range uses available history since Apr 20, 2026; less than a full year is stored.

Up next

Latest filing: 10-Q
filed Sep 14, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$3.24M
Trailing 12 months
Net income (TTM)
−$114,104
Trailing 12 months
Revenue growth YoY
+209.5%
Year over year
Operating margin
-2.7%
Trailing 12 months
P / E (TTM)
64.3
Trailing earnings · reciprocal yield 1.6%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$1.60M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.0%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
0.0%
Latest settlement
View all 122 metrics

Quarterly results

Revenue Net income Net loss
· $292,118 $32,647 '25 Q2 ▲1081.3% $308,318 $72,978 '25 Q3 ▲258.7% $1.95M $800,332 '25 Q4* ▼4.2% $103,899 −$46,301 '26 Q1 ▲46.2% $427,115 $35,810 '26 Q2 ▲130.2% $709,625 −$44,362 '26 Q3 ▼8.6% $1.78M $17,549 '26 Q4* LATEST ▲209.5% $321,576 −$123,101 '27 Q1

* Q4 derived as the full year minus Q1 to Q3.

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Buy Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 17.3 · elevated Equity put/call 0.56
Technical
price trend
Buy
50 / 200-day cross No cross
RSI (14) 53
neutral
MACD trend Positive
52-week position 86%
near high
Momentum
relative strength
Very Weak
1-month return −55%
trailing
YTD return −16%
this year
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
0.00% of float · ▬ 0.0% MoM · 1000.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Squeeze score 13
low risk · 0–100
Fundamentals
Strong
Revenue growth −68%
Y/Y
Gross margin 2396%
expanding
EPS growth +200%
Y/Y
Balance sheet $1.6M
net cash
Quant / Vol
risk profile
Very High
Volatility 1152%
annualized · 1-yr
Max drawdown −97%
past year
ATR 38.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 2 · 2
50 / 200-day cross
No cross Neutral
RSI (14)
53 Neutral
MACD trend
Positive Bullish
52-week position
86% Bullish
Market signals — smart money & positioning
No clear signal
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
0.00% of float · ▬ 0.0% MoM · 1000.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Price context
position in its available closing range
Range low $1 Now $4 · 86% Range high $5

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Medical Distribution — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
VNOV
VitaNova Life Sciences Corp
this stock
$34.18M — -68.3% — 0.0%
MCK
Mckesson Corp
 $120.10B +25.6% +3.1% 27.6 2.0%
COR
Cencora, Inc.
 $65.51B +1.6% +9.3% 25.5 2.1%
CAH
Cardinal Health Inc
 $59.90B +25.3% +14.2% — 3.2%
HSIC
Henry Schein Inc
 $9.44B +12.0% +5.9% 24.7 7.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Short & Settlement
Short Interest
Shares short
33
Days to cover
1000.0d
Change
0 sh
View
Short Volume
Short vol %
100%
As of
Oct 19, 2026
Short Total
View
Off-Exchange
Off-exchange %
100.0%
Week of
Apr 20, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$3.0M
Net income (FY)
$-37.3K
EPS diluted
$0.09
View
Filings
SEC Filings
Latest
10-Q
Filed
Sep 14, 2026
This year
7
View

Performance

5D 20D 120D MTD YTD
VNOV +62.0% -55.0% — +193.5% -16.2%
SPY -1.2% -0.6% +8.1% +0.8% +12.8%
vs SPY +63.2% -54.4% — +192.6% -28.9%
Key facts CIK 1699709